pioglitazone has been researched along with Angiogenesis, Pathologic in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 7.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 5.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 3.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Pioglitazone has advantage over rosiglitazone in lowering lipid and proinflammatory cytokines." | 2.74 | Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. ( Kumar, H; Mishra, M; Tripathi, K; Vijay, SK, 2009) |
| "Pioglitazone was given orally [10mg/kg/day] for 28 days and adiponectin intraperitoneally [2." | 1.56 | Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats. ( Abdul Sattar, M; Afzal, S; Eseyin, OA; Johns, EJ, 2020) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 1.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, J | 1 |
| Liu, Z | 1 |
| Zhang, L | 1 |
| Hu, X | 1 |
| Wang, Z | 1 |
| Ni, H | 1 |
| Wang, Y | 1 |
| Qin, J | 1 |
| Afzal, S | 1 |
| Abdul Sattar, M | 1 |
| Johns, EJ | 1 |
| Eseyin, OA | 1 |
| Schwabl, P | 1 |
| Payer, BA | 1 |
| Grahovac, J | 1 |
| Klein, S | 1 |
| Horvatits, T | 1 |
| Mitterhauser, M | 1 |
| Stift, J | 1 |
| Boucher, Y | 1 |
| Trebicka, J | 1 |
| Trauner, M | 1 |
| Angermayr, B | 1 |
| Fuhrmann, V | 1 |
| Reiberger, T | 1 |
| Peck-Radosavljevic, M | 1 |
| Nenicu, A | 1 |
| Körbel, C | 1 |
| Gu, Y | 1 |
| Menger, MD | 1 |
| Laschke, MW | 1 |
| Vijay, SK | 1 |
| Mishra, M | 1 |
| Kumar, H | 1 |
| Tripathi, K | 1 |
| Higuchi, A | 1 |
| Ohashi, K | 1 |
| Shibata, R | 1 |
| Sono-Romanelli, S | 1 |
| Walsh, K | 1 |
| Ouchi, N | 1 |
| Vucic, E | 1 |
| Dickson, SD | 1 |
| Calcagno, C | 1 |
| Rudd, JH | 1 |
| Moshier, E | 1 |
| Hayashi, K | 1 |
| Mounessa, JS | 1 |
| Roytman, M | 1 |
| Moon, MJ | 1 |
| Lin, J | 1 |
| Tsimikas, S | 1 |
| Fisher, EA | 1 |
| Nicolay, K | 1 |
| Fuster, V | 1 |
| Fayad, ZA | 1 |
| Keshamouni, VG | 1 |
| Arenberg, DA | 1 |
| Reddy, RC | 1 |
| Newstead, MJ | 1 |
| Anthwal, S | 1 |
| Standiford, TJ | 1 |
| Kasper, B | 1 |
| Ho, AD | 1 |
| Egerer, G | 1 |
| Kusuyama, T | 1 |
| Omura, T | 1 |
| Nishiya, D | 1 |
| Enomoto, S | 1 |
| Matsumoto, R | 1 |
| Takeuchi, K | 1 |
| Yoshikawa, J | 1 |
| Yoshiyama, M | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
2 trials available for pioglitazone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Diabetes Mellitus, Type 2; | 2009 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
9 other studies available for pioglitazone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Lung | 2020 |
Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Hemodynamics; Hypertension; Hypoglycemic Agen | 2020 |
Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Topics: Animals; Cell Movement; Disease Models, Animal; Hemodynamics; Human Umbilical Vein Endothelial Cells | 2014 |
Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; | 2014 |
Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetic Retinopathy; Hypoglycemic Agents; Isch | 2010 |
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortography; Atherosclerosis; Biomarkers; Contrast Media; | 2011 |
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
Topics: Amino Acid Motifs; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Ce | 2005 |
A new therapeutic approach in patients with advanced sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2005 |
Effects of treatment for diabetes mellitus on circulating vascular progenitor cells.
Topics: Actins; Adult; Atherosclerosis; Blood Glucose; Cell Proliferation; Diabetes Complications; Diabetes | 2006 |